ABSTRACT
Advances in perinatal and neonatal medicine have significantly improved survival rates of preterm infants. This improvement has been associated with substantial risk of neurodevelopmental impairments and with increased number of infants with special health care needs. Cerebral palsy is the most well known and potentially most disabling motor abnormality associated with prematurity. There has been limited progress in understanding the causes of cerebral palsy and in developing primary prevention strategies. Several studies have summarized the experimental evidence that supports possible neuroprotective effects of magnesium. Five randomized controlled trials of antenatal magnesium sulfate found a trend of reduced risk of cerebral palsy in preterm infants. Three meta-analyses using the data from these five trials found that magnesium sulfate given to women at risk of premature birth significantly reduced the risk of cerebral palsy without increasing the risk of perinatal or infant death.
How to cite this article
Constantinescu S, Denes M, Chilianu A, Vladareanu R. Magnesium Sulfate: Fetal Neuroprotective Role in Reducing the Risk of Cerebral Palsy. Donald School J Ultrasound Obstet Gynecol 2013;7(1):98-104.
Magnesium Sulfate: Fetal Neuroprotective Role in Reducing the Risk of Cerebral Palsy
